NCT01011296View on ClinicalTrials.gov

First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Healthy Volunteers
Interventions
DRUG

PF-04427429

Single 0.2mg dose of intravenous infusion

DRUG

PF-04427429

Single 1mg dose of intravenous infusion

DRUG

PF-04427429

Single 3 mg dose of intravenous infusion

Trial Locations (1)

85013

Pfizer Investigational Site, Phoenix

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01011296 - First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter